ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD 1 refractory melanoma from 2018 imo Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Prof Paolo Ascierto speaks to ecancer at ESMO 2018 in Munich about the ILLUMINATE 301 trial, a phase 3 randomised comparison of ipilimumab alone versus IMO-2125 combined with ipilimumab in subjects with anti PD 1 refractory melanoma.nnProf Ascierto recaps the findings of phase 1 and the likely timeline of phase 3.nnHe also discusses the relevant findings of CheckMate 067, also presented at ESMO 2018, which uses ipilimuma combined with nivolumab.
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)